Technology
Health
Biotechnology

Immuron

$7.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.49 (7.17%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Immuron and other stocks, options, ETFs, and crypto commission-free!

About

Immuron Ltd. engages in the research and development of oral immunotherapy treatments using dairy-derived antibody products for humans. It operates through the following segments: Research and Development; HyperImmune Products; and Corporate. Read More The Research and Development segment involves the R&D projects performed in Australia and Israel. The HyperImmune Products segment comprises of Travelan activities which occur in Australia, New Zealand, Canada, and the United States. The Corporate segment covers company activities. The company was founded on January 13, 1994 and is headquartered in Southbank, Australia.

Employees
Headquarters
Carlton, Victoria (VIC)
Founded
1994
Market Cap
24.32M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
4.75K
High Today
$7.35
Low Today
$6.75
Open Price
$6.76
Volume
1.90K
52 Week High
$14.29
52 Week Low
$5.26

Collections

Technology
Health
Biotechnology
Research And Development
2013 IPO

News

MarketBeatMar 6

Stock Price, News, & Analysis for IMMURON LTD/S

Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally.

5
Simply Wall StFeb 26

The Immuron Share Price Is Down 26% So Some Shareholders Are Getting Worried

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! In order to justify the effort of selecting individual stocks, it’s worth striving to beat the returns from a market index fund. But if you try your hand at stock picking, your risk returning less than the market. Unfortunately, that’s been the case for longer term Immuron Limited (ASX:IMC) shareholders, since the share price is down 26% in the last three years, falling well short of the market ...

9

Earnings

Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.